

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Maria Chaikou	Citizen of Greece	Novartis Pharma AG Lichtstrasse 35, 4056, Basel, Switzerland
Mathieu Paul-Léon Rigollet	Citizen of France	Novartis Pharma AG Lichtstrasse 35, 4056, Basel, Switzerland

(hereinafter "Inventor(s)"),

and **NOVARTIS PHARMA AG**, Lichtstrasse 35, 4056 Basel, Switzerland, a company organized under the laws of Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **NOVARTIS PHARMA AG** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **NOVARTIS PHARMA AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) listed on the attached APPENDIX A;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other

applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in Appendix A of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be

necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date.

Executed this _____ day of _____, 2024 .

Maria Chaikou

Witness: _____

Printed Name:

City, State and Country:

Witness: _____

Printed Name:


City, State and Country:

Executed this 18th day of July, 2024.



Mathieu Paul-Léon Rigollet

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Witness: 

Printed Name:

City, State and Country:

Witness: W. Wichert

Printed Name: Wibke Wichert

City, State and Country:

Lichtstrasse 35
4056 Basel
Switzerland


Executed this 23rd day of JULY, 2024 .

NOVARTIS PHARMA AG

BY _____

Printed Name:

Authorized Signatory

**SUDESHNA PATEKAR**
AUTHORIZED SIGNATORY**Laura Keller**
Lichtstrasse 35
4056 Basel
Switzerland

Witness: _____

Printed Name:

City, State and Country:

Witness: _____

Printed Name:

City, State and Country:

Anja WibbingLichtstrasse 35
4056 Basel
Switzerland**NOVARTIS PHARMA AG**

BY _____

Printed Name:

Authorized Signatory

**Claudia Cialeo**
Authorized Signatory

Witness: _____

Printed Name:

City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Witness: _____

Printed Name:

City, State and Country:

Anja WibbingLichtstrasse 35
4056 Basel
Switzerland

APPENDIX A

Case Reference	Country	Application Number	Filing Date	Grant Number
PAT059497-AT-UM	Austria	GM47/2024	2024.05.28	
PAT059497-AT-UM02	Austria			
PAT059497-AU-NP	Australia	2024203639	2024.05.30	
PAT059497-BE-NP	Belgium	2024/5298	2024.05.23	
PAT059497-BR-NP	Brazil	BR102024013445-1	2024.06.28	
PAT059497-CA-NP	Canada	3237624	2024.05.07	
PAT059497-CH-NP	Switzerland	CH000601/2024	2024.06.04	
PAT059497-CN-UM	China	2024211878998	2024.05.28	
PAT059497-DE-UM	Germany	202024000928.9	2024.05.10	
PAT059497-DE-UM02	Germany	202024001265.4	2024.07.02	
PAT059497-DK-UM	Denmark	202400038	2024.05.22	
PAT059497-EP-EPA	European Procedure	23188544.3	2023.07.28	
PAT059497-EP-EPA02	European Procedure	24171754.5	2024.04.22	
PAT059497-EP-EPA03	European Procedure	24183812.7	2024.06.21	
PAT059497-ES-NP	Spain	202430372	2024.05.10	
PAT059497-ES-UM	Spain	202430860	2024.05.10	
PAT059497-FR-UM	France	2405157	2024.05.21	
PAT059497-GR-UM	Greece	20240200385	2024.07.03	
PAT059497-HU-NP	Hungary			
PAT059497-IE-STP	Ireland	S2024/0414	2024.07.12	
PAT059497-IT-UM	Italy	202024000002443	2024.06.10	
PAT059497-JP-UM	Japan	2024-002348	2024.07.16	
PAT059497-KR-UM	South Korea / Republic of Korea	20-2024-0001274	2024.07.11	
PAT059497-MX-UM	Mexico	MX/u/2024/000214	2024.05.30	
PAT059497-NL-NP	Netherlands	2037761	2024.05.23	
PAT059497-NO-NP	Norway	20240512	2024.05.22	
PAT059497-SE-NP	Sweden	2450536-4	2024.05.17	
PAT059497-TR-UM	Turkey			
PAT059497-TW-UM	Taiwan	113205584	2024.05.30	
PAT059497-GB-NP	United Kingdom	2408006.1	2024.06.05	
PAT059497-US-NP	United States of America	18/743859	2024.06.14	
PAT059497-US-NP02	United States of America	18/743874	2024.06.14	

ASSIGNMENT

This Assignment Agreement is entered into by and between:

Maria Chaikou	Citizen of Greece	Novartis Pharma AG Lichtstrasse 35, 4056, Basel, Switzerland
Mathieu Paul-Léon Rigollet	Citizen of France	Novartis Pharma AG Lichtstrasse 35, 4056, Basel, Switzerland

(hereinafter "Inventor(s)"),

and **NOVARTIS PHARMA AG**, Lichtstrasse 35, 4056 Basel, Switzerland, a company organized under the laws of Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, **NOVARTIS PHARMA AG** is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to **NOVARTIS PHARMA AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of my/our right, title and interest for all countries of the world in and to

(1) all of my/our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) listed on the attached APPENDIX A;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other

applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorizes ASSIGNEE and their representatives to insert in Appendix A of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. I/We the Inventor(s) also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be


necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date.


Executed this 17th day of July, 2024.


 Maria Chaikou, Athens, Greece

Witness:


 Printed Name: AVRAMIDI KONSTANTINA-MARIA
 City, State and Country: ATHENS, GREECE 17/07/24

Witness:


 Printed Name: KOKKINIDIS CHRISTOS
 City, State and Country: ATHENS, GREECE 17/07/24

Executed this _____ day of _____, 2024.

Mathieu Paul-Léon Rigollet

Witness: _____

Printed Name:

City, State and Country:

Witness: _____

Printed Name:

City, State and Country:

Executed this 23 day of JULY, 2024.

NOVARTIS PHARMA AG

BY _____

Printed Name: _____

Authorized Signatory _____


SUDESHNA PATEKAR
AUTHORIZED SIGNATORY

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Witness: _____

Printed Name: _____

City, State and Country: _____

Anja Wibbing

Witness: _____

Printed Name: _____

City, State and Country: _____

NOVARTIS PHARMA AG

BY _____

Printed Name: _____

Authorized Signatory _____


Claudia Cialeo
Authorized Signatory

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Witness: _____

Printed Name: _____

City, State and Country: _____

Anja Wibbing

Witness: _____

Printed Name: _____

City, State and Country: _____

APPENDIX A

Case Reference	Country	Application Number	Filing Date	Grant Number
PAT059497-AT-UM	Austria	GM47/2024	2024.05.28	
PAT059497-AT-UM02	Austria			
PAT059497-AU-NP	Australia	2024203639	2024.05.30	
PAT059497-BE-NP	Belgium	2024/5298	2024.05.23	
PAT059497-BR-NP	Brazil	BR102024013445-1	2024.06.28	
PAT059497-CA-NP	Canada	3237624	2024.05.07	
PAT059497-CH-NP	Switzerland	CH000601/2024	2024.06.04	
PAT059497-CN-UM	China	2024211878998	2024.05.28	
PAT059497-DE-UM	Germany	202024000928.9	2024.05.10	
PAT059497-DE-UM02	Germany	202024001265.4	2024.07.02	
PAT059497-DK-UM	Denmark	202400038	2024.05.22	
PAT059497-EP-EPA	European Procedure	23188544.3	2023.07.28	
PAT059497-EP-EPA02	European Procedure	24171754.5	2024.04.22	
PAT059497-EP-EPA03	European Procedure	24183812.7	2024.06.21	
PAT059497-ES-NP	Spain	202430372	2024.05.10	
PAT059497-ES-UM	Spain	202430860	2024.05.10	
PAT059497-FR-UM	France	2405157	2024.05.21	
PAT059497-GR-UM	Greece	20240200385	2024.07.03	
PAT059497-HU-NP	Hungary			
PAT059497-IE-STP	Ireland	S2024/0414	2024.07.12	
PAT059497-IT-UM	Italy	202024000002443	2024.06.10	
PAT059497-JP-UM	Japan	2024-002348	2024.07.16	
PAT059497-KR-UM	South Korea / Republic of Korea	20-2024-0001274	2024.07.11	
PAT059497-MX-UM	Mexico	MX/u/2024/000214	2024.05.30	
PAT059497-NL-NP	Netherlands	2037761	2024.05.23	
PAT059497-NO-NP	Norway	20240512	2024.05.22	
PAT059497-SE-NP	Sweden	2450536-4	2024.05.17	
PAT059497-TR-UM	Turkey			
PAT059497-TW-UM	Taiwan	113205584	2024.05.30	
PAT059497-GB-NP	United Kingdom	2408006.1	2024.06.05	
PAT059497-US-NP	United States of America	18/743859	2024.06.14	
PAT059497-US-NP02	United States of America	18/743874	2024.06.14	

ASSIGNMENT

This Assignment Agreement is entered into by and between **NOVARTIS PHARMA AG**, Lichtstrasse 35, 4056 Basel, Switzerland, a company organized under the laws of Switzerland; and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland and **GENENTECH INC.**, 1 DNA Way, South San Francisco California 94080-4990 United States of America, organized and incorporated under the laws of the State of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **NOVARTIS PHARMA AG** confirms that **NOVARTIS PHARMA AG** has sold, assigned, and transferred, and does hereby sell, assign and transfer to **NOVARTIS AG** and **GENENTECH INC.**, its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) listed on the attached APPENDIX A;

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and

divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by **NOVARTIS PHARMA AG** if this sale, assignment and transfer had not been made.

NOVARTIS PHARMA AG hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s), Application Number(s), jurisdiction and title of said patent, utility model, or other application(s) when notified thereof and correct any typographical errors thereto. **NOVARTIS PHARMA AG** also hereby authorizes ASSIGNEE and their representatives to update the entity (company) address as needed or correct any typographical errors thereto.

NOVARTIS PHARMA AG hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such

jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 23rd day of JULY, 2024.

NOVARTIS PHARMA AG

BY

Printed Name:

Authorized Signatory

SUDESHNA PATEKAR
AUTHORIZED SIGNATORY

Witness:

Printed Name:

City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Witness:

Printed Name:

City, State and Country:

Anja Wibbing

Lichtstrasse 35
4056 Basel
Switzerland

NOVARTIS PHARMA AG

BY

Printed Name:

Authorized Signatory

Claudia Cialeo
Authorized Signatory

Witness:

Printed Name:

City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Witness:

Printed Name:

City, State and Country:

Anja Wibbing

Lichtstrasse 35
4056 Basel
Switzerland

Executed this 23 day of July, 2024.

NOVARTIS AG

BY Holger Petersen
Printed Name:
Authorized Signatory

Holger Petersen
Authorized Signatory

Witness: [Signature]
Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Witness: Anja Wibbing
Printed Name:
City, State and Country:

Anja Wibbing
Lichtstrasse 35
4056 Basel
Switzerland

NOVARTIS AG

BY Giulia Ceccarelli
Printed Name:
Authorized Signatory

GIULIA CECCARELLI
AUTHORIZED SIGNATORY

Witness: [Signature]
Printed Name:
City, State and Country:

Laura Keller
Lichtstrasse 35
4056 Basel
Switzerland

Witness: Anja Wibbing
Printed Name:
City, State and Country:

Anja Wibbing
Lichtstrasse 35
4056 Basel
Switzerland

Executed this 7 day of AUGUST, 2024.

GENENTECH, INC.

BY Derek Scott
Printed Name: DEREK SCOTT
Authorized Signatory

Witness: Catherine Misener
Printed Name: CATHERINE MISENER
City, State and Country: SO. SAN FRANCISCO, CA, UNITED STATES

Witness: Aaron Inciong
Printed Name: AARON INCIONG
City, State and Country: SO. SAN FRANCISCO, CA, UNITED STATES

APPENDIX A

Case Reference	Country	Application Number	Filing Date	Grant Number
PAT059497-AT-UM	Austria	GM47/2024	2024.05.28	
PAT059497-AT-UM02	Austria			
PAT059497-AU-NP	Australia	2024203639	2024.05.30	
PAT059497-BE-NP	Belgium	2024/5298	2024.05.23	
PAT059497-BR-NP	Brazil	BR102024013445-1	2024.06.28	
PAT059497-CA-NP	Canada	3237624	2024.05.07	
PAT059497-CH-NP	Switzerland	CH000601/2024	2024.06.04	
PAT059497-CN-UM	China	2024211878998	2024.05.28	
PAT059497-DE-UM	Germany	202024000928.9	2024.05.10	
PAT059497-DE-UM02	Germany	202024001265.4	2024.07.02	
PAT059497-DK-UM	Denmark	202400038	2024.05.22	
PAT059497-EP-EPA	European Procedure	23188544.3	2023.07.28	
PAT059497-EP-EPA02	European Procedure	24171754.5	2024.04.22	
PAT059497-EP-EPA03	European Procedure	24183812.7	2024.06.21	
PAT059497-ES-NP	Spain	202430372	2024.05.10	
PAT059497-ES-UM	Spain	202430860	2024.05.10	
PAT059497-FR-UM	France	2405157	2024.05.21	
PAT059497-GR-UM	Greece	20240200385	2024.07.03	
PAT059497-HU-NP	Hungary			
PAT059497-IE-STP	Ireland	S2024/0414	2024.07.12	
PAT059497-IT-UM	Italy	202024000002443	2024.06.10	
PAT059497-JP-UM	Japan	2024-002348	2024.07.16	
PAT059497-KR-UM	South Korea / Republic of Korea	20-2024-0001274	2024.07.11	
PAT059497-MX-UM	Mexico	MX/u/2024/000214	2024.05.30	
PAT059497-NL-NP	Netherlands	2037761	2024.05.23	
PAT059497-NO-NP	Norway	20240512	2024.05.22	
PAT059497-SE-NP	Sweden	2450536-4	2024.05.17	
PAT059497-TR-UM	Turkey			
PAT059497-TW-UM	Taiwan	113205584	2024.05.30	
PAT059497-GB-NP	United Kingdom	2408006.1	2024.06.05	
PAT059497-US-NP	United States of America	18/743859	2024.06.14	
PAT059497-US-NP02	United States of America	18/743874	2024.06.14	